Dr Anne Collins is a senior biotechnology executive with over 20 years’ global leadership in life sciences. As Sementis CEO, she drives the advancement of the Sementis Copenhagen Vector (SCV) platform, guiding the company towards clinical-stage therapeutic vaccines with a blend of scientific expertise and commercial acumen.
Her previous senior roles include Hospira (now Pfizer), Trajan Scientific & Medical, Mayne Pharma and Ipsen (UK). At Hospira, she helped establish biomanufacturing and biosimilars programs, gaining broad experience in international R&D and manufacturing strategy. She has also advised MedTech and pharma companies via the AusIndustry Entrepreneurs’ Programme.
Joining Sementis as COO in 2022, Dr Collins strengthened manufacturing capability and global networks. As CEO, she repositioned Sementis towards therapeutic allergy vaccines, refining design, manufacturing and regulatory strategies to support clinical progress.
Dr Collins is Adjunct Senior Industry Fellow at Adelaide University and is committed to strengthening South Australia’s biotech sector. Her expertise is instrumental in advancing SCV-PHAV into the clinic and building a competitive vaccine company.
Career
- Business Advisor Med Tech for Pharma and Advanced Manufacturing at AusIndustry
- General Manager for Microsampling at Trajan Scientific and Medical
- Associate Director for One2One BioServices at Hospira Global Biologics
- Senior Associate for Biomanufacturing at Faulding Pharmaceutical / Mayne Pharma
- Manager for Technical Affairs at Ipsen
Education
- Bachelor of Science (Honours) in Cell Biology from Oxford Brookes University
- Master of Science in Biochemical Engineering from University College London
- PhD in Biochemical Engineering from the University College London
- Master in Business Administration from The University of Adelaide